Brief: Elicera Therapeutics Q2 Operating Loss At SEK 2.89 Mln
Aug 29 (Reuters) - Elicera Therapeutics AB ELIC.ST: Q2 ADJUSTED EPS SEK -0.06 OPERATING LOSS FOR Q2 2025 AMOUNTED TO SEK -2,892,341 Source text: ID:nWkr2Frdrg Further company coverage: ELIC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application